# Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

> **NCT04469075** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- Skin Toxicity

## Interventions

- **DRUG:** Clindamycin Phosphate
- **DRUG:** Triamcinolone Acetonide

## Key facts

- **NCT ID:** NCT04469075
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-09
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469075, "Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04469075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*